Crucial role of phospholamban phosphorylation and s-nitrosylation in the negative lusitropism induced by 17β-estradiol in the male rat heart

Cellular Physiology and Biochemistry

Volumn 28, Issue 1, 2011, Pages 41-52

  Filice, Elisabetta ^a   Angelone, Tommaso ^a   De Francesco, Ernestina M ^a   Pellegrino, Daniela ^a   Maggiolini, Marcello ^a   Cerra, Maria C ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

17beta estradiol; Lusitropy; Rat Langendorff heart

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; ESTROGEN RECEPTOR BETA; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLAMBAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR PARAMETERS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ESTROGEN ACTIVITY; HEART MUSCLE CELL; HEART MUSCLE RELAXATION; HEART PERFORMANCE; HEART VENTRICLE FILLING; ISOLATED HEART; LUSITROPISM; MALE; NITROSYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN NITROSYLATION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

MAMMALIA; RATTUS;

EID: 80052005807     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000331712     Document Type: Article

References (55)

1. Lew R, Komesaroff P, Williams M, Dawood T, Sudhir K: Endogenous estrogens influence endothelial function in young men. Circ Res 2003;93:1127-1133. (Pubitemid 37485045)
2. Sudhir K, Chou TM, Messina LM, Hutchison SJ, Korach KS, Chatterjee K, Rubanyi GM: Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 1997;349:1146-1147. (Pubitemid 27168554)
3. Sudhir K, Chou TM, Chatterjee K, Smith EP, Williams TC, Kane JP, Malloy MJ, Korach KS, Rubanyi GM: Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 1997;96:3774-3777. (Pubitemid 27513460)
4. Kimura M, Sudhir K, Jones M, Simpson E, Jefferis AM, Chin-Dusting JP: Impaired acetylcholine-induces release of nitric oxide in the aorta of male aromatase-knockout mice: regulation of nitric oxide production by endogenous sex hormones in males. Circ Res 2003;93:1267-1271. (Pubitemid 37543067)
5. Shearman AM, Cupples LA, Demissie S, Peter I, Schmid CH, Karas RH, Mendelsohn ME, Housman DE, Levy D: Association between estrogen receptor gene variation and cardiovascular disease. JAMA 2003;290:2263-2270. (Pubitemid 37430558)
6. Maggiolini M, Picard D: The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 2010;204:105-114.
7. Filice E, Recchia AG, Pellegrino D, Angelone T, Maggiolini M, Cerra MC: A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat. J Physiol Pharmacol 2009;60:3-10.
8. Leite-Moreira AF: Current perspectives in diastolic dysfunction and diastolic heart failure. Heart 2006;92:712-718.
9. Angelone T, Filice E, Quintieri AM, Imbrogno S, Recchia A, Pulerà E, Mannarino C, Pellegrino D, Cerra MC : Beta3-adrenoceptors modulate left ventricular relaxation in the rat heart via the NO-cGMP-PKG pathway. Acta Physiol (Oxf) 2008;193:229-239. (Pubitemid 351783190)
10. Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, Mahata SK, Cerra MC: The antihypertensive Chromogranin A peptide Catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 2008;149:4780-4793.
11. Cerra MC, Gallo MP, Angelone T, Quintieri AM, Pulerà E, Filice E, Guérold B, Shooshtarizadeh P, Levi R, Ramella R, Brero A, Boero O, Metz-Boutigue MH, Tota B, Alloatti G: The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide. FASEB J 2008;22:3992-4004.
12. Cerra MC, De Iuri L, Angelone T, Corti A, Tota B: Recombinant N-terminal fragments of chromogranin-A modulate cardiac function of the Langendorffperfused rat heart. Basic Res Cardiol 2006;101:43-52. (Pubitemid 43323431)
13. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS: Protein Snitrosylation: purview and parameters. Nat Rev Mol Cell Biol 2005;6:150-166.
14. Garofalo F, Parisella ML, Amelio D, Tota B, Imbrogno S: Phospholamban Snitrosylation modulates Starling response in fish heart. Proc Biol Sci 2009;276:4043-4052.
15. Brutsaert DL, Sys SU: Relaxation and diastole of the heart. Physiol Rev 1989;69:1228-1315. (Pubitemid 19255838)
16. Vittone L, Mundiña-Weilenmann C, Mattiazzi A, Cingolani H: Physiologic and pharmacologic factors that affect myocardial relaxation. J Pharmacol Toxicol Methods 1994;32:7-18. (Pubitemid 24320433)
17. Cerra MC, Angelone T, Parisella ML, Pellegrino D, Tota B: Nitrite modulates contractility of teleost (Anguilla anguilla and Chionodraco hamatus, i.e. the Antarctic hemoglobinless icefish) and frog (Rana esculenta) hearts. Biochim Biophys Acta 2009;1787:849-855.
18. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, Katzenellenbogen BS, Katzenellenbogen JA: Pyrazole ligands: structure-affinity/ activity relationships and estrogen receptoralpha-selective agonists. J Med Chem 2000;43:4934-4947. (Pubitemid 32040974)
19. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA: Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 2001;44:4230-4251. (Pubitemid 33095330)
20. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, Oprea TI, Prossnitz ER: Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006;4:207-212.
21. Angelone T, Goumon Y, Cerra MC, Metz-Boutigue MH, Aunis D, Tota B: The emerging cardioinhibitory role of the hippocampal cholinergic neurostimulating peptide (HCNP). J Pharmacol Exp Ther 2006;318:336-344.
22. Angelone T, Pasqua T, Di Majo D, Quintieri AM, Filice E, Amodio N, Tota B, Giammanco M, Cerra MC: Distinct signalling mechanisms are involved in the dissimilar myocardial and coronary effects elicited by quercetin and myricetin, two red wine flavonols. Nutr Metab Cardiovasc Dis 2011;21:362-71.
23. Mendelsohn ME, Karas RH: Estrogen and the blood vessel wall. Curr Opin Cardiol 1994;9:619-626. (Pubitemid 24267789)
24. Gingerich S, Krukoff TL: Activation of ER: Activation of ERbeta increases levels of phosphorylated nNOS and NO production through a Src/PI3K/Aktdependent pathway in hypothalamic neurons. Neuropharmacology 2008;55:878-885.
25. Chu G, Kranias EG: Functional interplay between dual site phospholambam phosphorylation: insights from genetically altered mouse models. Basic Res Cardiol 2002;97:I43-48.
26. Lima B, Forrester MT, Hess DT, Stamler JS: S-nitrosylation in cardiovascular signaling. Circ Res 2010;106:633-646.
27. Penna C, Alloatti G, Gallo MP, Cerra MC, Levi R, Tullio F, Bassino E, Dolgetta S, mahata SK, Tota B, Pagliaro P: Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell Mol Neurobiol 2010;30:1171-1179.
28. Terrell AM, Crisostomo PR, Markel TA, Wang M, Abarbanell AM, Herrmann JL, Meldrum DR: Postischemic infusion of 17-beta-estradiol protects myocardial function and viability. J Surg Res 2008;146:218-224. (Pubitemid 351484136)
29. Dubey RK, Imthurn B, Barton M, Jackson EK: Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res. 2005;66:295-306. (Pubitemid 40471044)
30. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613. (Pubitemid 28502636)
31. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. (Pubitemid 34761611)
32. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000;407:538-541.
33. Deroo BJ, Buensuceso AV: Minireview: Estrogen receptor-beta: mechanistic insights from recent studies. Mol Endocrinol 2010;24:1703-1714.
34. Gabel SA, Walker VR, London RE, Steenbergen C, Korach KS, Murphy E: Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury. J Mol Cell Cardiol 2005;38:289-297. (Pubitemid 40215198)
35. Nikolic I, Liu D, Bell JA, Collins J, Steenbergen C, Murphy E: Treatment with an estrogen receptor-beta-selective agonist is cardioprotective. J Mol Cell Cardiol 2007,42:769-780. (Pubitemid 46527602)
36. Tota B, Cerra MC, Gattuso A: Catecholamines, cardiac natriuretic peptides and chromogranin A: evolution and physiopathology of a 'whip-brake' system of the endocrine heart. J Exp Biol 2010;213:3081-3103.
37. Fabiato A: Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol Cell Physiol 1983;245:C1-C14. (Pubitemid 14225289)
38. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA, Yellon DM, Latchman DS: Urocortin protects against ischemic and reperfusion injury via a MAPK dependent pathway. J Biol Chem 2000;275:8508-8514. (Pubitemid 30180198)
39. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL: The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA 2004;101:3697-3702 (Pubitemid 38338257)
40. Seddon M, Shah AM, Casadei B: Cardiomyocytes as effectors of nitric oxide signalling. Cardiovasc Res 2007;75:315-26. (Pubitemid 46961933)
41. Mendelsohn ME, Karas RH: Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-1587. (Pubitemid 40807497)
42. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC: Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999;399:597-601.
43. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, Hobai IA, Lemmon CA, Burnett AL, O'Rourke B, Rodriguez ER, Huang PL, Lima JA, Berkowitz DE, Hare JM: Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 2002;416:337-339.
44. Ziolo MT, Bers DM: The real estate of NOS signaling: location, location, location. Circ Res 2003;92:1279-1281. (Pubitemid 36773467)
45. Cerra MC, Pellegrino D: Cardiovascular cGMP-generating systems in physiological and pathological conditions. Curr Med Chem 2007;14:585-599. (Pubitemid 46477730)
46. Damilano F, Perino A, Hirsch E: PI3K kinase and scaffold functions in heart. Ann NY Acad Sci 2010;1188:39-45.
47. Wang M, Wang Y, Weil B, Abarbanell A, Herrmann J, Tan J, Kelly M, Meldrum DR: Estrogen receptor beta mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia. Am J Physiol Regul Integr Comp Physiol 2009;296:R972-978.
48. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC, Bender JR: Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 2000;87:677-682.
49. Patten RD, Pourati I, Aronovitz MJ, Baur J, Celestin F, Chen X, Michael A, Haq S, Nuedling S, Grohe C, Force T, Mendelsohn ME, Karas RH: 17betaestradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res 2004;95:692-699. (Pubitemid 39331929)
50. Urata Y, Ihara Y, Murata H, Goto S, Koji T, Yodoi J, Inoue S, Kondo T: 17beta-Estradiol protects against oxidative stress-induced cell death through the glutathione/glutaredoxin-dependent redox regulation of Akt in myocardiac H9c2 cells. J Biol Chem 2006;281:13092-13102. (Pubitemid 43855219)
51. Brittsan A, Kranias EG: Phospholamban and cardiac contractile function. J Mol Cell Cardiol 2000;32:2131-2139. (Pubitemid 32039765)
52. Mattiazzi A, Mundina-Weilenmann C, Guoxiang C, Vittone L, Kranias E: Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions. Cardiovascular Res 2005;68:366-75. (Pubitemid 41566556)
53. Shi Q, Feng J, Qu H, Cheng YY: A proteomic study of S-nitrosylation in the rat cardiac proteins in vitro. Biol Pharm Bull 2008;31:1536-1540.
54. Lin J, Steenbergen C, Murphy E, Sun J: Estrogen receptor-beta activation results in S-nitrosylation of proteins involved in cardioprotection. Circulation 2009;120:245-254.
55. MacLennan DH, Kranias EG: Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003;4:566-577. (Pubitemid 36773408)